ALPMY (Astellas Pharma) Receivables Turnover : 0.73 (As of Mar. 2025)

View and export this data going back to 2008. Start your Free Trial

What is Astellas Pharma Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Astellas Pharma's Revenue for the three months ended in Mar. 2025 was $3,081 Mil. Astellas Pharma's average Accounts Receivable for the three months ended in Mar. 2025 was $4,217 Mil. Hence, Astellas Pharma's Receivables Turnover for the three months ended in Mar. 2025 was 0.73.

Astellas Pharma Receivables Turnover Historical Data

The historical data trend for Astellas Pharma's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Receivables Turnover Chart

Astellas Pharma Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Receivables Turnover

Get a 7-Day Free Trial

3.60

3.43

3.54

3.16

3.28

Astellas Pharma Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Receivables Turnover	Get a 7-Day Free Trial															0.79	0.82	0.85	0.83	0.73

Competitive Comparison of Astellas Pharma's Receivables Turnover

For the Drug Manufacturers - General subindustry, Astellas Pharma's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma's Receivables Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Receivables Turnover falls into.

Save Embed

;

Save Embed

;

Astellas Pharma Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Astellas Pharma's Receivables Turnover for the fiscal year that ended in Mar. 2025 is calculated as

	Receivables Turnover (A: Mar. 2025 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Mar. 2025 )	/ (	(Accounts Receivable (A: Mar. 2024 )	+	Accounts Receivable (A: Mar. 2025 ))	/	count )
=	12829.423	/ (	(3570.885	+	4243.494)	/	2 )
=	12829.423	/	3907.1895
=	3.28

Astellas Pharma's Receivables Turnover for the quarter that ended in Mar. 2025 is calculated as

	Receivables Turnover (Q: Mar. 2025 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Mar. 2025 )	/ (	(Accounts Receivable (Q: Dec. 2024 )	+	Accounts Receivable (Q: Mar. 2025 ))	/	count )
=	3081.319	/ (	(4190.982	+	4243.494)	/	2 )
=	3081.319	/	4217.238
=	0.73

Astellas Pharma (OTCPK:ALPMY) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Astellas Pharma Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Astellas Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (OTCPK:ALPMY) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

ALPMF:USA 4503:Japan YPH:Germany

Address

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411

Website

http://www.astellas.com

Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.